Italian API maker rebounds; Patheon takes opioid work;

> Montreal-based Labopharm (TSX: DDS; NASDAQ: DDSS) says that Italy's Gruppo Angelini, which makes the active ingredient for the once-daily depression treatment Trazodone, has resolved all manufacturing process issues raised by the FDA. Announcement

> In an agreement between QRxPharma (ASX: QRX and OTCQX: QRXPY) and Patheon (TSX:PTI), the latter will manufacture clinical supplies of QRxPharma's controlled-release Dual-Opioid formulation for 12-hour pain relief. Release

> The University of Iowa Pharmaceuticals (UIP) has been cleared by the FDA to manufacture and test an aseptically filled, sterile prescription drug for a commercial client. Release

> TruScan 1.3.0, Ahura Scientific's handheld Raman spectrometer for raw material identification and finished product authentication, now boasts availability in the Chinese and German languages. Release

> Schering-Plough says it will expand a Montreal manufacturing facility to the tune of $28 million. Article

And Finally... The Top 15 Women in Pharma. Start slideshow ⇒

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.